HILPDA Is a Prognostic Biomarker and Correlates With Macrophage Infiltration in Pan-Cancer

被引:32
|
作者
Liu, Chengdong [1 ]
Zhou, Xiaohan [2 ]
Zeng, Hanyi [1 ]
Wu, Dehua [2 ]
Liu, Li [1 ]
机构
[1] Southern Med Univ, Nanfang Hosp, Dept Infect Dis, Guangzhou, Peoples R China
[2] Southern Med Univ, Nanfang Hosp, Dept Radiat Oncol, Guangzhou, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2021年 / 11卷
关键词
HILPDA; pan-cancer; tumor associated macrophages; TCGA; immunossuppression; CARCINOMA; HIG2;
D O I
10.3389/fonc.2021.597860
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The protein hypoxia-inducible lipid droplet-associated (HILPDA) is differentially expressed in various tumors. However, its role and correlation with immune cell infiltration in most tumors remain unclear. Methods: HILPDA expression was analyzed in pan-cancer data from The Cancer Genome Atlas (TCGA) database. The influence of HILPDA in clinical prognosis was evaluated using clinical survival data from TCGA. Enrichment analysis of HILPDA was conducted using the R package "clusterProfiler." We downloaded the immune cell infiltration score of TCGA samples from published articles and analyzed the correlation between the magnitude of immune cell infiltration and HILPDA expression. Results: HILPDA was highly expressed and associated with worse overall survival, disease-specific survival, and progression-free interval in most tumor types. In addition, HILPDA expression was significantly associated with the glycolysis pathway and infiltration of immune cells. Tumor-associated macrophage (TAM) infiltration increased in tissues with high HILPDA expression in most tumor types. Immunosuppressive genes, such as PD-L1, PD-1, TGFB1, and TGFBR1 were positively correlated with HILPDA. Conclusions: Our study suggests that HILPDA is a marker of poor prognosis. High HILPDA may contribute to TAM infiltration and be associated with tumor immunosuppression status.
引用
下载
收藏
页数:10
相关论文
共 50 条
  • [31] Potential Value of PRKDC as a Therapeutic Target and Prognostic Biomarker in Pan-Cancer
    Yang, Xiawei
    Sun, Xuyong
    Yang, Feng
    Lan, Liugen
    Wen, Ning
    Li, Haibin
    Research Square, 2021,
  • [32] CISD3 is a prognostic biomarker and therapeutic target in pan-cancer
    Jie Li
    Han Yang
    Yixin Qi
    Peng Yu
    Xiahui Han
    Zongliang Zhang
    Kai Zhao
    Xinbao Yin
    Guanqun Zhu
    Xuechuan Yan
    Zaiqing Jiang
    Xuezhen Ma
    Tianzhen He
    Ke Wang
    Scientific Reports, 14 (1)
  • [33] Systematic pan-cancer analysis identifies cGAS as an immunological and prognostic biomarker
    Chen, Peng
    Yang, Xian
    Wang, Peiyuan
    He, Hao
    Chen, Yujie
    Yu, Lingfeng
    Fang, Huipeng
    Wang, Feng
    Huang, Zhijian
    ANNALS OF TRANSLATIONAL MEDICINE, 2023,
  • [34] P4HA1, a Prognostic Biomarker that Correlates With Immune Infiltrates in Lung Adenocarcinoma and Pan-Cancer
    Zhao, Qi
    Liu, Junfeng
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2021, 9
  • [35] RAMP1 as a novel prognostic biomarker in pan-cancer and osteosarcoma
    Xie, Long
    Xiao, Weiwei
    Fang, Hangqi
    Liu, Guoqiang
    PLOS ONE, 2023, 18 (10):
  • [36] Pan-cancer analysis identifies BIRC5 as a prognostic biomarker
    Anna Fäldt Beding
    Peter Larsson
    Khalil Helou
    Zakaria Einbeigi
    Toshima Z. Parris
    BMC Cancer, 22
  • [37] Potential value of PRKDC as a therapeutic target and prognostic biomarker in pan-cancer
    Yang, Xiawei
    Yang, Feng
    Lan, Liugen
    Wen, Ning
    Li, Haibin
    Sun, Xuyong
    MEDICINE, 2022, 101 (27) : E29628
  • [38] The value of WNT5A as prognostic and immunological biomarker in pan-cancer
    Feng, Yingtong
    Wang, Yuanyong
    Guo, Kai
    Feng, Junjun
    Shao, Changjian
    Pan, Minghong
    Ding, Peng
    Liu, Honggang
    Duan, Hongtao
    Lu, Di
    Wang, Zhaoyang
    Zhang, Yimeng
    Zhang, Yujing
    Han, Jing
    Li, Xiaofei
    Yan, Xiaolong
    ANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (08)
  • [39] C1QTNF6 is a Prognostic Biomarker and Related to Immune Infiltration and Drug Sensitivity: A Pan-Cancer Analysis
    Liu, Wei
    Zhang, Jian
    Xie, Tao
    Huang, Xiaoting
    Wang, Baiyao
    Tian, Yunhong
    Yuan, Yawei
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [40] Pan-Cancer Analysis and Experimental Validation of CEND1 as a Prognostic and Immune Infiltration-Associated Biomarker for Gliomas
    Ma, Jinyang
    Lang, Bojuan
    Wang, Lei
    Zhou, Youdong
    Fu, Changtao
    Tian, Chunlei
    Xue, Lixin
    MOLECULAR BIOTECHNOLOGY, 2024,